

ALLERGAN INC  
Form 8-K  
January 04, 2007

Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
January 4, 2007**

Date of Report (Date of Earliest Event Reported)

**ALLERGAN, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State of Incorporation)

**1-10269**  
(Commission File Number)

**95-1622442**  
(IRS Employer  
Identification Number)

**2525 Dupont Drive  
Irvine, California 92612**  
(Address of Principal Executive Offices) (Zip Code)  
**(714) 246-4500**  
(Registrant's Telephone Number, Including Area Code)

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

Exhibit Index

---

**Table of Contents**

**Item 8.01. Other Events.**

On January 2, 2007, Allergan, Inc. ( Allergan ) consummated the acquisition of all of the outstanding capital stock of Groupe Cornéal Laboratoires and its subsidiaries ( Cornéal ) pursuant to a Stock Sale and Purchase Agreement ( Purchase Agreement ) dated October 31, 2006, by and among Allergan and Allergan Holdings France, SAS, an indirect wholly owned subsidiary of Allergan, on the one hand, and Waldemar Kita, the controlling stockholder of Cornéal, the European Pre-Floatation Fund II and the other minority stockholders of Cornéal, on the other hand.

Under the Purchase Agreement, Allergan purchased the outstanding capital stock of Cornéal for an aggregate purchase price of EUR 177,200,219, or approximately \$US 233,948,411, subject to possible post-closing adjustments based on a final determination of Cornéal s debt and cash levels.

The foregoing description of the Purchase Agreement and the transactions consummated thereby is qualified in its entirety by reference to the Purchase Agreement attached as Exhibit 10.1 to Allergan s Current Report on Form 8-K filed November 2, 2006.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

- 2.1 Stock Sale and Purchase Agreement, dated October 31, 2006, by and among Allergan, Inc., Allergan Holdings France, SAS, Waldemar Kita, the European Pre-Floatation Fund II and the other minority stockholders of Cornéal (incorporated by reference to Exhibit 10.1 to Allergan s Current Report on Form 8-K filed November 2, 2006).
-

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALLERGAN, INC.**

Date: January 4, 2007

By: /s/ Matthew J. Maletta  
Name: Matthew J. Maletta  
Title: Vice President,  
Assistant General Counsel and Assistant  
Secretary

---

**Table of Contents**

**Exhibit Index**

**Exhibit**

**Description of Exhibit**

2.1	Stock Sale and Purchase Agreement, dated October 31, 2006, by and among Allergan, Inc., Allergan Holdings France, SAS, Waldemar Kita, the European Pre-Floation Fund II and the other minority stockholders of Cornéal (incorporated by reference to Exhibit 10.1 to Allergan's Current Report on Form 8-K filed November 2, 2006).
-----	---